<DOC>
	<DOCNO>NCT00156910</DOCNO>
	<brief_summary>This 60 week study include double-blind phase follow open-label extension phase .</brief_summary>
	<brief_title>A Study Using Botulinum Toxin Type A Headache Prophylaxis Migraine Patients With Frequent Headaches</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Frequent migraine ( &gt; =15 headache day per month ) &gt; =4 distinct headache episode last &gt; =4 hour &gt; =50 % baseline headache day migraine/probable migraine day Previous use botulinum toxin serotype immunization botulinum toxin serotype Any medical condition put patient increase risk exposure BOTOX Diagnosis complicate migraine , chronic tensiontype headache , hypnic headache , hemicrania continuum , new daily persistent headache Use prophylactic headache medication within 28 day prior week 4 Unremitting headache last continuously throughout 4week baseline period Known suspect Temporomandibular Disorders ( TMD ) Diagnosis fibromyalgia Beck depression inventory score &gt; 24 week4 Psychiatric problem may interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>